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Volume 56, Number 1 Bush 111runoff in terms of the success of the intervention. The third
question is about your medical management. You did mention
that the patients were on aspirin and Plavix, or one of the two.
I’m curious as to whether you put these patients on statins or
how involved you get in the medical management. There are
certainly data that suggest improved patency and better out-
comes with patients who are on statins and angiotensin-converting
enzyme (ACE) inhibitors. I don’t know if you’re involved with
that. Probably my only concern with the manuscript is that you do
make the statement that the failure of these procedures for TASC
C and D lesions leads to a decrease in limb salvage, and I’m not
really sure that you showed that. The reason I say that is that they
are moving on to having open revascularization, and at that point,
your limb salvage rate is still very similar to previously published
data for redo procedures. So I don’t know if it’s really that the
failure of the procedure leads to a problem or if it just indicates
more severe disease and they have to go on to another procedure,
like they might traditionally have to. Thanks for allowing me to
review this. I look forward to your responses.
Dr Omar Al-Nouri. Thank you, Dr Rossi. With regard to
your first question, when you break it down, if you take away the
claudication patients who were intervened on and you look at just
the critical limb ischemia, the limb salvage is pretty comparable to
open bypass. However, when SFA interventions fail, I think several
recent studies have shown that it might not have an absolute effect
on negative limb salvage, but it does change the distal target
bypass, and that might decrease the patency of the open revascu-
larization and make the bypass more difficult subsequently when
you do have a failed SFA intervention, which could lead to de-
creased limb salvage. When we looked at the numbers for our
patients, we used several CPT codes, and the 500 angioplasties that
we looked at, those were not only just balloon angioplasty/
stenting, but that included iliac interventions as well as diagnostic
angiograms. So it was a large amount of data to go through to find
just those 42 limbs. I think you’re right, we specifically looked at
patients that just underwent SFA stenting, we excluded patients
that underwent only balloon angioplasty, thus, we’re selecting out
for these more advanced lesions and maybe setting it up for
potentially having a failure. I’m sorry, the third and fourth ques-
tions? I apologize.
Dr Rossi.One was about medical management as far as using
statins or ACE inhibitors, and the other was about the assumption
that the failed percutaneous intervention leads to more difficult
procedures for limb salvage.
Dr Al-Nouri. For the medical management, we have always
put those patients on 30 days of Plavix postoperatively. We are
pretty involved in the statin therapy with the medical doctors as
well, so we do place the patients on statins if they were not on
statins before and they have an indication to be on statin therapy.
We talked about excellent vessel runoff, good vessel runoff, or poor
vessel runoff, with a score of 3, 2, and 1, respectively, but did not
break the patients down into these categories to see if they have a
better patency rate the higher the runoff score is. We are still
accruing data from the Veteran Affairs; once we have a more
substantial number of patients, we will definitely look at patency
rates broken down by runoff score.
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patients considered high medical risk who would have previ-
ously been precluded from more traditional open bypass proce-
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iDrKarl Illig (Rochester, NY). I have good news and bad news
or you. The good news is that your article was very well presented
nd your data were very clear, and I thank you very much for that.
he bad news is that I have to pile on a little bit with regard to the
rior discussant’s fourth question. I don’t think you have really
nswered what you have set out to ask. Rather, you’ve really sort of
ust reaffirmed the definitions of TASC C and D lesions. In other
ords, your results really are nomore than the definitions of TASC
and D. The question you’re trying to answer is if you initially
pproach a patient using endovascular techniques, do you burn
our bridges; are youmaking things worse? A way of answering this
ould be to take your stented patients and blindly determine what
surgical bypass would have entailed, and then, when those who
ail do so, compare what they end up requiring. If a patient would
ave required bypass to the popliteal level originally and then after
failed stent requires a pedal bypass, you’ve burned your bridges.
e careful about saying that just because some patients went on to
mputation that you’re doing anything good or bad – that is the
atural history of this disease, and you cannot say that you have
hanged anything without some sort of control group.
Dr Al-Nouri. No, it’s a very good question. We are also
ooking at our open bypass experience within the same time period.
he idea when we set out looking at our SFA experience was how
an we tie this in exactly with a failed SFA intervention? Does it
urn our bridge in terms of the distal target that they might have?
o it’s one thing we are going to look at, as well as compare and
ook at the open bypass surgery and see, in this patient who failed
nd subsequently went on to have an open bypass, if it was the
atency rate as opposed to someone who did not fail initially and
ee if those are comparable or not.
Dr Illig. Because your number is so small, for this article you
ould really very easily figure out what their bypass would have
een and then what their bypass ended up being afterward.
Dr Al-Nouri. Yes.
Dr Philip Goodney (Lebanon, NH). That was nicely pre-
ented. I just wondered if you had calculated amputation-free
urvival curves or major adverse limb event curves. They would
elp to put into context some of the discussions that you’ve had
ith those who have come up to talk about your article. Patency is
ependent upon how long a patient lives, of course, and you put a
ot of stents into some very sick patients, and that might affect the
verall limb salvage rate, just because a patient might not live long
nough to get their amputation. Similarly, limb-specific outcome
easures, such as the major adverse limb events, which is one of
he Society for Vascular Surgery objective performance goals that
e’ll use to compare these results to open surgery, might effec-
ively contribute to your study. I wonder if you have that informa-
ion, and if you don’t, will you put it in your manuscript?
Dr Al-Nouri. I don’t have that information on hand right
ow. We’re still looking at it. But we are looking at the amputation-
ree survival and it probably will be in the manuscript. You know,
ooking at amputation-free survival, that number might not be as
ignificant as patency, and that’s kind of why we wanted to specif-
cally look at patency, because we did have a significant percentage
f patients (36%) who were claudicants. Those patients should
urvive. So, amputation-free survival might not be the best indica-
or in patients with critical limb ischemia.INVITED COMMENTARYRuth L. Bush, MD, MPH, Temple, Tex
The utilization of lower extremity endovascular interven-
tions for the treatment of both claudication and critical limb
ischemia has dramatically increased in the last decade. Part of
this increase may be accounted for because of technological
advances and part may be due to more aggressive treatment ofures. Dr Al-Nouri and colleagues have provided a detailed
nalysis of their institutional experience with endovascular in-
erventions in the superficial femoral artery. Despite the small
ize of the study group and the cohort heterogeneity, their
esults have produced some important treatment options and
ssential patient messages that can be used by the peripheral
nterventionalist.
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July 2012112 BushFirst, patients with critical limb ischemia (CLI) by definition
generally represent a group of persons with a heavier burden of
atherosclerotic disease. As a result, these unfortunate patients also
have more concomitant comorbidities than persons with claudica-
tion alone. Taking steps to reduce perioperative risk such as max-
imizing atherosclerotic risk factor management medically, using
local or regional anesthetic modalities, employing advanced
wound care techniques, or even discussing observation or primary
amputation alone are all fundamental to patient care and commu-
nication. Thus, management of CLI requires a multidisciplinary
team approach and detailed patient communication and under-
standing of the possible negative outcomes. Conversely, claudi-
cants tend to have less diffuse peripheral vascular disease, better
tibial runoff vessels, and also in many situations, better functional
outcomes. Even though failed superficial femoral artery (SFA)
interventions in patients with lifestyle-limiting claudication (espe-
cially TransAtlantic Inter-Society [TASC] C and D compared with
A and B lesions) may not necessarily lead to amputation or bypass,
the authors recommend primary bypass in those with adequate
autogenous conduit.
Second, both a clear assessment of the extent of lower extrem-
ity atherosclerotic disease and an extensive armamentarium of
potential interventions are keys to success. In Dr Al-Nouri’s series,
o
a6% of the patients had claudication alone, whereas the other 64%
ad either rest pain or tissue loss. While an isolated intervention in
he SFA may be adequate for improved flow in a claudicant, a
erson with CLI needs restoration of in-line, pulsatile flow to heal
wound or alleviate rest pain. As these patients have more diffuse
isease with multiple arterial segments involved, a combination of
nterventions may be necessary. In cases with poor tibial runoff or
heavily diseased SFA, failure rates of isolated SFA interventions
ill be higher. It is not surprising that this study demonstrated that
nterventions performed in CLI patients with more advanced
ASC C and D lesions were more likely to fail and need either
ypass or amputation. With more advanced SFA disease, these
atients probably had coexisting tibial disease and more heavily
alcified vessels. It would be interesting to seeDr Al-Nouri’s results
n the treatment of multisegment disease in patients with CLI.
Nonetheless, Dr Al-Nouri and colleagues had a 40% and 46%
econdary patency rate for TASC C and D lesion interventions,
espectively, and a 93% overall limb salvage rate. They conclude
hat in patients with claudication and advanced lesions, perhaps
pen bypass should be the treatment of choice. However, in
atients with CLI, an aggressive approach to limb salvage, whether
pen or endovascular based upon medical risk, may be a justifiable
nd acceptable suggestion to primary amputation.
